CAMP/TILs project presentation
When checkpoint inhibitors fail; could ACT be an option?
Welcome to the presentation of the CAMP project ”Expansion of GMP Compliant Tumor Infiltrating Lymphocytes (TILs) in Xuri bioreactor.”
Speakers: Stina Wickström and Katrin Markland
Title: When checkpoint inhibitors fail; could ACT be an option?
Time: Monday 16/11 at 14:00
Registration: included in registration for ATMP Sweden 2020 virtual (registration now closed)
CAMP focusses on the development of technology, infrastructure and processes towards creating the means for novel cell or gene based pharmaceuticals to be produced in a GMP compliant fashion. One of the great examples of this is the Tumor Infiltrating Lymphocyte project which was a collaboration between Karolinska Institutet, Cytiva and Vecura/KUH towards the production of patient derived TILs for use in a clinical trial against checkpoint inhibitor resistant metastatic malignant melanoma. In this seminar you will hear from Stina Wickström at Karolinska Institutet and Katrin Markland from Vecura on the steps and processes taken to be able to deliver Adoptive Cell Therapy (ACT) in the form of patient derived TILs and DC vaccine under clinical trial and the lifesaving outcomes seen.
Read the latest news about the project here.